BioSpace News Archive

Biosimulation is an important part of systems biology and helps in the discovery and development of new drugs, in the area of drug metabolism and in the modeling of biomedical systems that are complex.

According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes, announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Saqib Islam, Chief Executive Officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 8:50 a.m. Eastern Standard Time.

Modular Bioscience, an early stage biotechnology company based in Silicon Valley, announced that it has executed a definitive agreement with the University of Illinois at Urbana-Champaign for an exclusive global patent license to a novel artificial restriction enzyme platform.

Corporate satellite presentation and scientific posters highlight new AmplideX® testing kits

Nordic Nanovector ASA announces that members of its management team will present at Jefferies Virtual Healthcare Conference, taking place 2-4 June 2020.

According to a study conducted by Persistence Market Research (PMR), demand for anti-inflammatory drugs and biologics for treating Crohn’s disease will gain traction in the near future. PMR forecasts that the global market for Crohn’s disease is set to reach US$ 4,474.8 Million by 2024-end, growing at a CAGR of 3% during the assessment period.

Anika Therapeutics, Inc. announced that Sylvia Cheung, Chief Financial Officer, has informed the Board of Directors of her decision, following a period of transition, to step away from her role at Anika effective August 21, 2020.

Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 3,700 shares of common stock to one new employee.